Pipeline

Development programs

The AmorphOX® technology can be applied to a broad scope of active ingredients, including small and large molecules. It is already being used across multiple research programs in both preclinical and clinical phases.

Development program Technology Partnership Preclinical Clinical Registration Approved

Launched products

Read more

Scientific Presentation

Bioavailability and Stability of Epinephrine Nasal Powder Formulations for Treatment of Anaphylaxis

With prompt administration, epinephrine is an effective life-saving treatment of anaphylactic shock. 

Insights

OX390 program and BARDA partnership

Designing a rescue medication for adulterated opioids: Edward Kim, MD, MBA and Chief Medical Officer at Orexo shares his insights into the evolving opioid epidemic.

Partnership

Partner with us

We power partners´ proprietary projects with the AmorphOX® technology.

Related pages

OX472

GLP-1 agonist, semaglutide

OX472 is an innovative intranasal formulation of semaglutide, a GLP-1 receptor agonist, developed using Orexo’s proprietary AmorphOX® technology. Orexo is also exploring AmorphOX with semaglutide for oral administration.

Vaccine

Advancing a new generation of vaccines

Vaccines represent a key research area for Orexo, and early data highlights the potential of AmorphOX® to enable thermostable, needle-free nasal vaccines.

OX390

For overdoses caused by adulterated drugs

OX390 for overdoses caused by adulterated drugs, is developed by Orexo in partnership with the Biomedical Advanced Research and Development Authority (BARDA), which is part of the US department of health and human services.

OX640

Redefining emergency treatment for anaphylaxis

OX640 is Orexo’s innovative intranasal powder formulation of epinephrine, designed to provide rapid onset and reliable dosing for the treatment of severe allergic reactions, including anaphylaxis.

Izipry™

High-dose naloxone to address synthetic opioid overdose

Izipry is designed to revive people who have got an overdose caused by synthetic opioids, such as fentanyl. The drug is powered by the amorphOX, a powder-based technology, which means it does not freeze and makes it ideal in regions with cold climate.

 

Orexo

Launched products

By applying its specialized drug delivery expertise to well-known active ingredients, Orexo has successfully advanced multiple candidates from development to global commercialization.